Efficacy of indomethacin in in vitro fertilisation treatment in the modified natural cycle.

Indomethacin is known to be a strong inhibitor of ovulation in the spontaneous menstrual cycle. Therefore we assume that the use of indomethacin prior to follicle aspiration in IVF-treatment in the modified natural cycle (IVF-MNC) significantly decreases the number of patients with one or more premature ovulations compared to placebo. To test this hypothesis we designed a double-blinded placebo-controlled randomised trial with two groups of 60 participants undergoing IVF or ICSI treatment in the modified natural cycle. The study medication, indomethacin (Indocid®) 50 mg or placebo, was taken three times a day, starting on the day of ovulation triggering and ending on the morning of the follicle aspiration (total of 7 capsules per cycle) up to a maximum of six cycles.

Primary outcome is the number/percentage of patients per study group that have one or more ovulations prior to follicle aspiration. Secondary outcome is the number/percentage of patients per study group that achieve an ongoing pregnancy (defined as an intact intra-uterine pregnancy at 12 weeks gestation).

Indomethacin is known to be a strong inhibitor of ovulation in the spontaneous menstrual cycle. Therefore we assume that the use of indomethacin prior to follicle aspiration in IVF-treatment in the modified natural cycle (IVF-MNC) significantly decreases the number of patients with one or more premature ovulations compared to placebo.

N/A

Use of indomethacin (Indocid®) 50 mg versus placebo during IVF-treatment in the modified natural cycle.

Dosage scheme: three times a day, starting on the day of ovulation triggering and ending on the morning of the follicle aspiration (total of 7 capsules per cycle).